Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. The company was founded in 1976 and is based in Minneapolis, Minnesota.
TECH Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for BIO-TECHNE Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that BIO-TECHNE Corp ranked in the 14th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 87%. The most interesting components of our discounted cash flow analysis for BIO-TECHNE Corp ended up being:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 97. Its equity weight surpasses that of 78.16% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 12.7% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
TECH's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 47.06% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of BIO-TECHNE Corp? See ENDP, MOH, RSCF, ZBH, and ZYXI.
The “Mesenchymal Stem Cells Market” Research Report 2020-2027 is a specialized and in-depth study of the Mesenchymal Stem Cells industry with a focus on the global market trend. The report aims to provide an overview of global Mesenchymal Stem Cells
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021, at 8:00 a.m. CST to review second quarter 2021 financial results.
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was Bio-Techne Corporation (NASDAQ:TECH). Is TECH a good stock to buy? […]
Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 2:00 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.